Skip to main content
. 2015 Sep 8;6(32):33217–33225. doi: 10.18632/oncotarget.5202

Figure 2. Survivals of patients with MLL-PTD AML.

Figure 2

Kaplan-Meier estimates of A. event-free survival and B. overall survival according to age, and C. event-free survival and D. overall survival according to the mutation status of DNMT3A in patients with MLL-PTD associated AML.